UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16
OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of ~~December 2025~~ January 2026

Commission File Number 001-42468

Cellyan Biotechnology Co., Ltd ~~(Registrant’s Name)~~

(Registrant’s Name)

Room B1, 5/F., Well Town Industrial Building,
13 Ko Fai Road, Yau Tong, Kowloon
Hong Kong
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

INFORMATION CONTAINED IN THIS FORM 6-K REPORT

AsOn ~~previously~~January ~~disclosed~~12, on2026, Cellyan Biotechnology Co., Ltd (the ~~report~~“Company”) onreceived ~~Form~~a letter from the Listings Qualifications Department of The Nasdaq Capital Market (“Nasdaq”) ~~6-K~~notifying the Company that the minimum closing bid price per share for its class A ordinary shares of ~~Cellyan~~par ~~Biotechnology~~value Coof US$0.,001 ~~Ltd~~each (~~f.k.a.~~“Class A ~~Hong Kong~~Ordinary ~~Pharma~~Shares”) ~~Digital~~was ~~Technology~~below ~~Holdings~~$1.00 ~~Limited),~~for a ~~Cayman~~period ~~Islands~~of ~~exempted~~30 ~~company with~~consecutive ~~limited~~business ~~liability~~days (and that the “Company”) atdid not meet the ~~annual~~minimum ~~general~~bid price ~~meeting~~requirement ofset ~~shareholders~~forth in Nasdaq Listing Rule 5550(a)(2). The Nasdaq notification letter does not result in the immediate delisting of the Company’s ~~held~~Class onA ~~December~~Ordinary 12Shares, ~~2025, it~~and ~~was~~the ~~approved~~shares ~~and~~will ~~authorized,~~continue ~~among~~to ~~others,~~trade ~~that~~uninterrupted under the symbol “HKPD.”

Pursuant to Nasdaq Listing Rule 5810(ic)(3)(A), the anCompany ~~increase~~has a compliance period of ~~the~~one ~~authorized~~hundred ~~share~~eighty ~~capital~~(180) ofcalendar ~~the~~days, ~~Company~~or ~~from~~until ~~US$100~~July 13,~~000~~ ~~divided~~2026 ~~into~~(the ~~100~~“Compliance Period”),~~000,000~~ to ~~ordinary~~regain ~~shares~~compliance ofwith ~~par~~Nasdaq’s ~~value~~minimum ofbid $0price requirement.~~001~~ ~~each~~If at any time during the Compliance Period, tothe USclosing bid price per share of the Company's Class A Ordinary Shares is at least $1~~,000,000~~.00 ~~divided~~for ~~into~~a 1minimum of ten (10) consecutive business days,~~000,000,000~~ ~~ordinary~~Nasdaq ~~shares~~will provide ofthe ~~par~~Company ~~value~~a written confirmation of ~~US$0~~compliance and the matter will be closed.~~001;~~

~~(ii)~~In anthe ~~amendment~~event of the ~~authorized~~Company ~~share~~does ~~capital~~not ofregain compliance by July 13, 2026, the Company ~~from~~may ~~US$1,000,000~~be ~~divided~~eligible ~~into~~for 1an additional 180 calendar day grace period. To qualify,~~000,000,000~~ ~~ordinary~~the ~~shares~~Company ofwill ~~par~~be required to meet the continued listing requirement for market value of ~~$0.001~~publicly ~~each,~~held toshares ~~US$1,000,000~~and ~~divided~~all ~~into~~other 1initial listing standards for the Nasdaq Capital Market,~~000,000,000~~ ~~ordinary~~with ~~shares~~the exception of ~~par~~the ~~value~~bid price requirement, and will need to provide written notice of ~~US$0.001~~its ~~each,~~intention ~~comprising~~to ~~(i)~~cure ~~940~~the deficiency during the second compliance period,~~000,000~~ ~~class~~including Aby ~~ordinary~~effecting ~~shares~~a ofreverse ~~par~~share ~~value~~split, ofif ~~US$0~~necessary.~~001~~ ~~each~~If ~~and~~the Company chooses to implement a reverse share split, it must complete the split no later than ten (ii10) 60business days prior to July 13,~~000~~ 2026,~~000~~ ~~class~~or Bthe ~~ordinary~~expiration of ~~shares~~the ofsecond ~~par~~compliance ~~value~~period ofif ~~US$0~~granted.~~001 each;~~

~~(iii)~~On ~~the~~January ~~English~~16, ~~name~~2026, of the Company beissued ~~changed~~a ~~from~~press release ~~“Hong~~entitled ~~Kong Pharma Digital Technology Holdings Limited” to~~ “Cellyan Biotechnology Co., Ltd”, ~~and~~Receives ~~the~~Nasdaq ~~Chinese~~Notice ~~name~~ of ~~“生研生物公司”~~Bid bePrice ~~adopted as the dual foreign name of the Company to replace its existing Chinese name of “港药数字科技控股有限公司~~Deficiency.” ~~with~~A ~~effect~~copy ~~from the date on which the Registrar~~ of ~~Companies in~~ the ~~Cayman~~please Islands issues a Certificate of Incorporation on Change of Name confirming that the new name has been registered, and each of the directors and the secretary and the registered office provider of the Company be and release is ~~hereby~~filed ~~authorized severally to do all such acts and things and execute all such documents~~ as ~~he/she/it~~Exhibit ~~may~~99.1 ~~consider necessary, desirable, appropriate or expedient~~ to ~~implement~~this ~~and/or~~Current ~~give~~Report ~~effect~~on toForm ~~the~~6-K ~~proposed change of company name~~ and tois ~~attend~~incorporated toherein ~~any~~by ~~necessary registration and/or filing for and on behalf of the Company; and~~reference.

(iv) the Fourth Amended and Restated Memorandum and Articles of Association of the Company be approved and adopted as the memorandum and articles of association of the Company in substitution for, and to the exclusion of, the existing third amended and restated memorandum and articles of association of the Company, and each of the directors and the secretary and the registered office provider of the Company be and is hereby authorized severally to do all such acts and things and execute all such documents as he/she/it may consider necessary, desirable, appropriate or expedient to implement the adoption of the Fourth Amended and Restated Memorandum and Articles of Association.

Attached to this report on Form 6-K as Exhibit 1.1 is a copy of the Certificate of Incorporation on Change of Name and Exhibit 1.2 is a copy of the Fourth Amended and Restated Memorandum and Articles of Association of the Company.

EXHIBIT INDEX

Exhibits

Exhibit No.		Description
1.1		Certificate of Incorporation on Change of Name
99.1		Press Release
1.2		Fourth Amended and Restated Memorandum and Articles of Association

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Cellyan Biotechnology Co., Ltd.

	By:	/s/ Chenyu Liang
	Name:	Chenyu Liang
	Title:	Director and Chief Executive Officer

Date: ~~December~~January 3016, ~~2025~~2026

Filing Compare · Cellyan Biotechnology Co., Ltd